Cargando…

Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma

IMPORTANCE: Immune checkpoint inhibitors have been approved for use as a second-line therapy for hepatocellular carcinoma (HCC) in patients who previously received sorafenib. Pembrolizumab has shown substantial antitumor activity and a favorable toxicity profile as a second-line treatment of HCC. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiang, Chi-leung, Chan, Sik-kwan, Lee, Shing-fung, Wong, Irene Oi-ling, Choi, Horace Cheuk-wai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816108/ https://www.ncbi.nlm.nih.gov/pubmed/33464318 http://dx.doi.org/10.1001/jamanetworkopen.2020.33761

Ejemplares similares

First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Chiang, Chi-Leung, et al.
Publicado: (2021)

Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer
por: Lee, Shing Fung, et al.
Publicado: (2021)

Cost-Effectiveness of Intranasal Live-Attenuated Influenza Vaccine for Children: A Systematic Review
por: Chan, Kenneth Sik-Kwan, et al.
Publicado: (2022)

Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis
por: Chan, Sik-Kwan, et al.
Publicado: (2022)

Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis
por: Chan, Sik-Kwan, et al.
Publicado: (2022)

Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway
por: Lo, Regina Cheuk-Lam, et al.
Publicado: (2018)

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
por: Watson, Tina R., et al.
Publicado: (2020)

Latent Tuberculosis Infection Testing Strategies for HIV-Positive Individuals in Hong Kong
por: Wong, Ngai Sze, et al.
Publicado: (2019)

Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
por: Shi, Yafei, et al.
Publicado: (2021)

Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States
por: Hu, Jia, et al.
Publicado: (2022)

Efficacy of Mobile Instant Messaging–Delivered Brief Motivational Interviewing for Parents to Promote Physical Activity in Pediatric Cancer Survivors: A Randomized Clinical Trial
por: Cheung, Ankie Tan, et al.
Publicado: (2022)

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
por: Rittberg, Rebekah, et al.
Publicado: (2023)

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial
por: Merle, Philippe, et al.
Publicado: (2023)

Autologous hematopoietic stem cell transplantation for high-risk brain tumors in children
por: Cheuk, Daniel Ka Leung, et al.
Publicado: (2007)

Sox9 confers stemness properties in hepatocellular carcinoma through Frizzled-7 mediated Wnt/β-catenin signaling
por: Leung, Carmen Oi-Ning, et al.
Publicado: (2016)

Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer
por: Zheng, Li, et al.
Publicado: (2022)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
por: Su, Dan, et al.
Publicado: (2021)

Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
por: Saberzadeh-Ardestani, Bahar, et al.
Publicado: (2023)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer
por: Chongqing, Tan, et al.
Publicado: (2021)

Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Choe, Jee H., et al.
Publicado: (2022)

Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong
por: Loong, Herbert H., et al.
Publicado: (2020)

PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma
por: Leung, Carmen Oi-ning, et al.
Publicado: (2015)

Variation of stemness markers expression in tumor nodules from synchronous multi-focal hepatocellular carcinoma – an immunohistochemical study
por: Lo, Regina Cheuk-lam, et al.
Publicado: (2017)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
por: Franchi, Matteo, et al.
Publicado: (2022)

Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer
por: Park, Chan Su, et al.
Publicado: (2022)

Sex‐specific analysis of microRNA profiles in HBV‐associated cirrhosis by small RNA‐sequencing
por: Chan, Kristy Kwan‐Shuen, et al.
Publicado: (2022)

Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Takahashi, Masato, et al.
Publicado: (2023)

Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non–Small Cell Lung Cancer
por: Popat, Sanjay, et al.
Publicado: (2022)

Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes
por: Vashisht, Rohit, et al.
Publicado: (2023)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Trends in gender of authors of original research in oncology among major medical journals: a retrospective bibliometric study
por: Lee, Shing Fung, et al.
Publicado: (2021)

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
por: Qin, Shukui, et al.
Publicado: (2023)

Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes
por: Ma, Bosco Hon-Ming, et al.
Publicado: (2023)

Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab
por: Truong, Phu, et al.
Publicado: (2016)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
por: Wu, Meiyu, et al.
Publicado: (2022)

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2021)

Establishment and characterization of a novel primary hepatocellular carcinoma cell line with metastatic ability in vivo
por: Cheung, Phyllis Fung-Yi, et al.
Publicado: (2014)

Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy
por: Kawahara, Takashi, et al.
Publicado: (2019)

Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
por: Loong, Herbert H., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ns5t4d0hlvaveveploh729e6ft